Latest News for: novartis ag

Edit

Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | ...

GetNews 21 Mar 2025
Key companies developing therapies for Sickle Cell Disease are - Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Addmedica, Medunik USA, Bristol Myers Squibb Co., Sanofi SA, Bluebird ...
Edit

Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by ...

GetNews 21 Mar 2025
In December 2024, Incyte (Nasdaq ... NSCLC includes several subtypes ... Key companies developing therapies for Non-Small Cell Lung Cancer are - Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., F.
Edit

Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, ...

GetNews 20 Mar 2025
Some of the key takeaways from the Parkinson’s Disease Pipeline Report. ... Parkinson’s Disease Overview ... KM-819. FAScinate Therapeutics ... P2B001 ... Key companies developing therapies for Parkinson’s Disease are - Pfizer Inc., Novartis AG, F.
Edit

Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies ...

GetNews 17 Mar 2025
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Bristol-Myers Squibb, TG Therapeutics, Hoffmann-La Roche, Atara Biotherapeutics, Immunic ...
Edit

Autistic Disorder Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | ...

GetNews 14 Mar 2025
In March 2024, SciSparc Ltd. (Nasdaq ... SB-121 ... Hoffmann-La Roche Ltd, Curemark, LLC, Zynerba Pharmaceuticals, Inc, Q BioMed Inc., PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Axial Therapeutics, Novartis AG, STALICLA, and others ... 1 ... 2.
Edit

Retinitis Pigmentosa Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight ...

GetNews 14 Mar 2025
... Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics, Sun Pharma Advanced Research Company, and others.
Edit

Chronic Plaque Psoriasis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports ...

GetNews 13 Mar 2025
... Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others.
Edit

Global Juvenile Idiopathic Arthritis Diagnostic Market Poised for Steady Growth, Projected to Reach USD 9,302.8 Million by 2034 Driven by Rising Prevalence and Technological Innovations | FMI

Pharmiweb 13 Mar 2025
In 2023, the market generated revenues of USD 6,042.9 million, reflecting its vital role in pediatric healthcare ... India ... Novartis International AG partnered with Genentech Inc ... Novartis International AG Bristol-Myers Squibb Zydus Cadila Genentech Inc ... T.
Edit

Global Cancer Gene Therapy Market Poised for Remarkable Growth, Projected to Reach USD 3,142.2 Million by 2034 Driven by Personalized Medicine and Targeted Therapies | FMI

Pharmiweb 10 Mar 2025
The global cancer gene therapy market is on the cusp of significant expansion, with sales expected to rise from USD 1,822.2 million in 2024 to a staggering USD 3,142.2 million by 2034 ... Access Key Market Insights ... Merck KGaA Novartis AG AstraZeneca Plc.
Edit

Meningitis Treatment Market Outlook to Reach USD 234.8 Million by 2034, Driven by Rising Disease Incidence & Advanced Therapeutics– Latest Report by Transparency Market Research Inc

Pharmiweb 06 Mar 2025
Novartis AG, ,Bio-med (P) Ltd., Nuron Biotech, Inc., Pfizer Inc., Baxter International Inc., Merck & Co ... Key players include Novartis AG, Bio-med (P) Ltd., Nuron Biotech, Inc., Pfizer Inc., Baxter International Inc., Merck & Co.
Edit

Oligonucleotide Synthesis Market worth $19.7 billion by 2029 | MarketsandMarkets™

GetNews 05 Mar 2025
"The North American market is projected to grow at the highest CAGR during the Forecast" ... Probes accounted for the second-largest segment of the synthesized oligos product segment in 2023 ... (US), Azenta, Inc ... Ltd ... (US) and Novartis AG (Switzerland) ... Mr.
Edit

Age-related Macular Degeneration Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR

GetNews 04 Mar 2025
Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US)" ... Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), and others.
Edit

Pneumoconiosis Market Expected to rise, 2032 | Abbott, Eli Lilly, Sun Pharma, Sanofi, Novo Nordisk, ...

GetNews 04 Mar 2025
Several key pharmaceutical companies, including Abbott, Eli Lilly, Sun Pharma, Sanofi, Novo Nordisk, Novartis, AstraZeneca, Merck & Co., Pfizer, Svizera Healthcare, F ... Novartis ... Hoffmann La Roche AG.
×